Central Serous Chorioretinopathy: Etiology, Course and Prognosis

Central Serous Chorioretinopathy Clinical Trial

Official title:

Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01378130
• Other study ID #: EK 180/2011
• Status: Completed
• Phase: N/A
• First received: June 20, 2011
• Last updated: April 25, 2013
• Start date: April 2011
• Est. completion date: April 2013

Study information

• Verified date: April 2013
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food Safety
• Study type: Observational

Clinical Trial Summary

Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. During this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Description:

Patients with central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna. All patients undergo ETDRS visual acuity measurement, Pelli-Robson contrast examination, Amsler-Grid testing, questionnaire testing, ophthalmologic examination, SD-OCT and polarization-sensitive OCT, fundus autofluorescence, fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry. Patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent form

• Age over 18 years

• acute episode of Central Serous Chorioretinopathy

• Symptoms for less than two weeks

• no treatment on study eye

Exclusion Criteria:

• bad compliance

• protected patient group (pregnant women)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Locations

Country	Name	City	State
Austria	Vienna Gerenal Hospital	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Outcome	OCT, Visus	2 years	No
Secondary	Subclinical Data	FA findings, retinal sensitivity in Microperimetry, contrast sensitivity, Amsler Grid Test	2 years	No